Literature DB >> 15870886

WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear.

C Gourley1, A J W Paige1,2, K J Taylor1, D Scott1, N-J Francis1, R Rush1, C M Aldaz3, J F Smyth1, H Gabra1,2.   

Abstract

WWOX is a candidate tumour suppressor gene that exhibits LOH or homozygous deletion in several tumour types. As well as the predominant full-length transcript (variant 1) there also exist alternatively spliced transcripts found previously only in malignant tissue. It has been suggested that proteins encoded by these variants may interfere with normal WWOX function in a dominant negative fashion. The most prevalent alternate transcript demonstrated in ovarian cancer is variant 4, which lacks exons 6-8. Here, we report the first comparison of the mRNA expression of WWOX variants 1 and 4 in human ovarian tumours and normal ovaries, and correlate expression with clinical data. We demonstrate significantly lower WWOX variant 1 expression in tumours than in normal ovaries. This reduction was not associated with any specific clinical subgroup. Variant 4 was expressed at low levels, and significantly associated with high grade and advanced stage ovarian cancer. Furthermore, tumours co-expressing variant 4 and relatively high levels of variant 1 showed significantly worse survival than tumours expressing variant 1 alone. However, variant 4 was also frequently identified in non-malignant ovarian tissue. These results support the role of WWOX variant 1 as a suppressor of ovarian tumourigenesis, but the role of variant 4 remains speculative.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15870886      PMCID: PMC4166600          DOI: 10.3892/ijo.26.6.1681

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  28 in total

1.  Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma.

Authors:  K Ge; J DuHadaway; W Du; M Herlyn; U Rodeck; G C Prendergast
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  WWOX: a candidate tumor suppressor gene involved in multiple tumor types.

Authors:  A J Paige; K J Taylor; C Taylor; S G Hillier; S Farrington; D Scott; D J Porteous; J F Smyth; H Gabra; J E Watson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

3.  WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.

Authors:  A K Bednarek; K J Laflin; R L Daniel; Q Liao; K A Hawkins; C M Aldaz
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

4.  Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus.

Authors:  P L Paris; J S Witte; P A Kupelian; H Levin; E A Klein; W J Catalona; G Casey
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

5.  WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer.

Authors:  Sai Yendamuri; Tamotsu Kuroki; Francesco Trapasso; Adam C Henry; Kristoffel R Dumon; Kay Huebner; Noel N Williams; Larry R Kaiser; Carlo M Croce
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

6.  Genetic analysis of benign, low-grade, and high-grade ovarian tumors.

Authors:  H Iwabuchi; M Sakamoto; H Sakunaga; Y Y Ma; M L Carcangiu; D Pinkel; T L Yang-Feng; J W Gray
Journal:  Cancer Res       Date:  1995-12-15       Impact factor: 12.701

7.  Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma.

Authors:  N Nishida; Y Fukuda; H Kokuryu; T Sadamoto; G Isowa; K Honda; Y Yamaoka; M Ikenaga; H Imura; K Ishizaki
Journal:  Int J Cancer       Date:  1992-07-30       Impact factor: 7.396

8.  Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma.

Authors:  Tamotsu Kuroki; Francesco Trapasso; Takeshi Shiraishi; Hansjuerg Alder; Koshi Mimori; Masaki Mori; Carlo M Croce
Journal:  Cancer Res       Date:  2002-04-15       Impact factor: 12.701

9.  Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer.

Authors:  Zhining Wang; H Shuen Lo; Howard Yang; Sheryl Gere; Ying Hu; Kenneth H Buetow; Maxwell P Lee
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

10.  5'-End RET splicing: absence of variants in normal tissues and intron retention in pheochromocytomas.

Authors:  Hervé Le Hir; Nicolas Charlet-Berguerand; Vittorio de Franciscis; Claude Thermes
Journal:  Oncology       Date:  2002       Impact factor: 2.935

View more
  20 in total

1.  WWOX protein expression in normal human tissues.

Authors:  Maria I Nunez; John Ludes-Meyers; C Marcelo Aldaz
Journal:  J Mol Histol       Date:  2006-08-29       Impact factor: 2.611

2.  WWOX induces apoptosis and inhibits proliferation of human hepatoma cell line SMMC-7721.

Authors:  Ben-Shun Hu; Jing-Wang Tan; Guo-Hua Zhu; Dan-Feng Wang; Xian Zhou; Zhi-Qiang Sun
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

3.  Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Hiroshi Handa; Yoshiko Sasaki; Hikaru Hattori; Lobna Alkebsi; Tetsuhiro Kasamatsu; Takayuki Saitoh; Takeki Mitsui; Akihiko Yokohama; Norifumi Tsukamoto; Morio Matsumoto; Hirokazu Murakami
Journal:  Oncol Lett       Date:  2017-07-26       Impact factor: 2.967

Review 4.  WWOX gene and gene product: tumor suppression through specific protein interactions.

Authors:  Zaidoun Salah; Rami Aqeilan; Kay Huebner
Journal:  Future Oncol       Date:  2010-02       Impact factor: 3.404

Review 5.  Role of WW domain proteins WWOX in development, prognosis, and treatment response of glioma.

Authors:  Shin-Yi Liu; Ming-Fu Chiang; Yu-Jen Chen
Journal:  Exp Biol Med (Maywood)       Date:  2014-11-27

6.  Cloning of WWOX gene and its growth-inhibiting effects on ovarian cancer cells.

Authors:  Zhoufang Xiong; Sha Hu; Zehua Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-06-17

Review 7.  Strategies of oncogenic microbes to deal with WW domain-containing oxidoreductase.

Authors:  Yao Chang; Yu-Yan Lan; Jenn-Ren Hsiao; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-07

8.  Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme.

Authors:  Katarzyna Kosla; Elzbieta Pluciennik; Agata Kurzyk; Dorota Jesionek-Kupnicka; Radzislaw Kordek; Piotr Potemski; Andrzej K Bednarek
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

9.  Oncosuppressor proteins of fragile sites are reduced in cervical cancer.

Authors:  Enrico Giarnieri; Nicola Zanesi; Arianna Bottoni; Mauro Alderisio; Ankica Lukic; Aldo Vecchione; Vincenzo Ziparo; Carlo Maria Croce; Rita Mancini
Journal:  Cancer Lett       Date:  2009-08-22       Impact factor: 8.679

10.  The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX.

Authors:  Ileana Aderca; Catherine D Moser; Manivannan Veerasamy; Ahmad H Bani-Hani; Ruben Bonilla-Guerrero; Kadra Ahmed; Abdirashid Shire; Sophie C Cazanave; Damian P Montoya; Teresa A Mettler; Lawrence J Burgart; David M Nagorney; Stephen N Thibodeau; Julie M Cunningham; Jin-Ping Lai; Lewis R Roberts
Journal:  J Hepatol       Date:  2008-06-09       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.